Eisai, Elan Fined $214 Million For U.S. Promotion Of Zonegran
This article was originally published in PharmAsia News
Executive Summary
Eisai has agreed to pay $11 million to the U.S. government to settle its share of charges it and Elan Pharmaceuticals promoted Eisai's Zonegran (zonisimide) epilepsy drug in violation of FDA rules